Prognostic value of follistatin-like 3 in human invasive breast cancer

Autor: Fernando M. Reis, Henrique L. Couto, Marcelo A. Buzelin, Nivaldo H. Toppa, Enrrico Bloise, Alberto J. Wainstein
Rok vydání: 2017
Předmět:
Zdroj: Oncotarget
ISSN: 1949-2553
Popis: // Henrique L. Couto 1, 2 , Marcelo A. Buzelin 3 , Nivaldo H. Toppa 4 , Enrrico Bloise 5 , Alberto J. Wainstein 2 and Fernando M. Reis 1 1 Division of Human Reproduction and Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil 2 Department of Oncology, Hospital Alberto Cavalcanti, Belo Horizonte, Minas Gerais, Brazil 3 Instituto Moacyr Junqueira, Belo Horizonte, Minas Gerais, Brazil 4 Laboratorio Analys Patologia, Belo Horizonte, Minas Gerais, Brazil 5 Department of Morphology, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil Correspondence to: Fernando M. Reis, email: fmreis@ufmg.br Keywords: FSTL3, FLRG, follistatin, activin, breast cancer Received: August 20, 2016 Accepted: January 10, 2017 Published: February 02, 2017 ABSTRACT Follistatin-like 3 (FSTL3) binds and inactivates activin, a growth factor involved with cell growth and differentiation. We have previously shown FSTL3 overexpression in invasive breast cancers, but its clinical relevance remained unexplored. Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer. A cohort of 154 women diagnosed with invasive breast cancer between 2008 and 2012 was followed up for 5 years. Tumor samples were processed by immunohistochemistry to detect FSTL3 expression in tumor epithelium. FSTL3 expression was classified semiquantitatively and tested for possible correlation with age, menopause status, stage, tumor histological type and grade, estrogen receptor, progesterone receptor, and HER2 expression. Survival plots with Kaplan-Mayer statistics were used to assess whether FSTL3 expression predicted disease-free survival. Our findings show that FSTL3 staining was unrelated to menopausal status, histological type, disease stage, or receptor profile. However, the intensity of FSTL3 immunostaining correlated inversely with tumor size (r = -0.366, p
Databáze: OpenAIRE